Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

720 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Validation of the SSTR-RADS 1.0 for the structured interpretation of SSTR-PET/CT and treatment planning in neuroendocrine tumor (NET) patients.
Grawe F, Ebner R, Geyer T, Beyer L, Winkelmann M, Sheikh GT, Eschbach R, Schmid-Tannwald C, Cyran CC, Ricke J, Bartenstein P, Heimer MM, Faggioni L, Spitzweg C, Fabritius MP, Auernhammer CJ, Ruebenthaler J. Grawe F, et al. Among authors: bartenstein p. Eur Radiol. 2023 May;33(5):3416-3424. doi: 10.1007/s00330-023-09518-y. Epub 2023 Mar 25. Eur Radiol. 2023. PMID: 36964768 Free PMC article.
Prognostic value of the International Metabolic Prognostic Index for lymphoma patients receiving chimeric antigen receptor T-cell therapy.
Winkelmann M, Blumenberg V, Rejeski K, Bücklein VL, Ruzicka M, Unterrainer M, Schmidt C, Dekorsy FJ, Bartenstein P, Ricke J, von Bergwelt-Baildon M, Subklewe M, Kunz WG. Winkelmann M, et al. Among authors: bartenstein p. Eur J Nucl Med Mol Imaging. 2023 Apr;50(5):1406-1413. doi: 10.1007/s00259-022-06075-2. Epub 2022 Dec 14. Eur J Nucl Med Mol Imaging. 2023. PMID: 36513818
Cost-Effectiveness Analysis of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer.
Mehrens D, Kramer KKM, Unterrainer LM, Beyer L, Bartenstein P, Froelich MF, Tollens F, Ricke J, Rübenthaler J, Schmidt-Hegemann NS, Herlemann A, Unterrainer M, Kunz WG. Mehrens D, et al. Among authors: bartenstein p. J Natl Compr Canc Netw. 2023 Jan;21(1):43-50.e2. doi: 10.6004/jnccn.2022.7070. J Natl Compr Canc Netw. 2023. PMID: 36634610
An Analysis of the Distribution of PSMA PET/CT-Positive Lymph Nodes and Their Coverage by Different Elective Nodal Radiation Volumes in Postoperative Prostate Cancer Patients.
Trapp C, Oliinyk D, Rogowski P, von Bestenbostel R, Ganswindt U, Li M, Eze C, Bartenstein P, Beyer L, Ilhan H, Sheikh G, Unterrainer L, Stief C, Westhofen T, Kunz WG, Unterrainer M, Belka C, Schmidt-Hegemann NS. Trapp C, et al. Among authors: bartenstein p. J Nucl Med. 2023 Jun;64(6):918-923. doi: 10.2967/jnumed.122.265159. Epub 2023 Feb 2. J Nucl Med. 2023. PMID: 36732055 Free article.
Investigation of image-based lesion and kidney dosimetry protocols for 177Lu-PSMA-I&T therapy with and without a late SPECT/CT acquisition.
Resch S, Takayama Fouladgar S, Zacherl M, Sheikh GT, Liubchenko G, Rumiantcev M, Unterrainer LM, Wenter V, Bartenstein P, Ziegler SI, Ilhan H, Beyer L, Böning G, Delker A. Resch S, et al. Among authors: bartenstein p. EJNMMI Phys. 2023 Feb 9;10(1):11. doi: 10.1186/s40658-023-00529-8. EJNMMI Phys. 2023. PMID: 36757516 Free PMC article.
Metabolic patterns on [18F]FDG PET/CT in patients with unresectable stage III NSCLC undergoing chemoradiotherapy ± durvalumab maintenance treatment.
Holzgreve A, Taugner J, Käsmann L, Müller P, Tufman A, Reinmuth N, Li M, Winkelmann M, Unterrainer LM, Nieto AE, Bartenstein P, Kunz WG, Ricke J, Belka C, Eze C, Unterrainer M, Manapov F. Holzgreve A, et al. Among authors: bartenstein p. Eur J Nucl Med Mol Imaging. 2023 Jul;50(8):2466-2476. doi: 10.1007/s00259-023-06192-6. Epub 2023 Mar 23. Eur J Nucl Med Mol Imaging. 2023. PMID: 36951991 Free PMC article.
Prognostic value of pre-infusion tumor growth rate for patients with lymphoma receiving chimeric antigen receptor T-cell therapy.
Winkelmann M, Blumenberg V, Rejeski K, Quell C, Bücklein VL, Ingenerf M, Unterrainer M, Schmidt C, Dekorsy FJ, Bartenstein P, Ricke J, von Bergwelt-Baildon M, Subklewe M, Kunz WG. Winkelmann M, et al. Among authors: bartenstein p. Cytotherapy. 2023 Sep;25(9):986-992. doi: 10.1016/j.jcyt.2023.03.007. Epub 2023 Apr 11. Cytotherapy. 2023. PMID: 37055322
Staging of lymphoma under chimeric antigen receptor T-cell therapy: reasons for discordance among imaging response criteria.
Winkelmann M, Blumenberg V, Rejeski K, Bücklein VL, Ingenerf M, Unterrainer M, Schmidt C, Dekorsy FJ, Bartenstein P, Ricke J, von Bergwelt-Baildon M, Subklewe M, Kunz WG. Winkelmann M, et al. Among authors: bartenstein p. Cancer Imaging. 2023 May 15;23(1):44. doi: 10.1186/s40644-023-00566-7. Cancer Imaging. 2023. PMID: 37189191 Free PMC article.
Is PSMA PET/CT cost-effective for the primary staging in prostate cancer? First results for European countries and the USA based on the proPSMA trial.
Holzgreve A, Unterrainer M, Calais J, Adams T, Oprea-Lager DE, Goffin K, Lopci E, Unterrainer LM, Kramer KKM, Schmidt-Hegemann NS, Casuscelli J, Stief CG, Ricke J, Bartenstein P, Kunz WG, Mehrens D. Holzgreve A, et al. Among authors: bartenstein p. Eur J Nucl Med Mol Imaging. 2023 Oct;50(12):3750-3754. doi: 10.1007/s00259-023-06332-y. Epub 2023 Jul 10. Eur J Nucl Med Mol Imaging. 2023. PMID: 37428216 Free PMC article.
Reliability and practicability of PSMA-RADS 1.0 for structured reporting of PSMA-PET/CT scans in prostate cancer patients.
Grawe F, Blom F, Winkelmann M, Burgard C, Schmid-Tannwald C, Unterrainer LM, Sheikh GT, Pfitzinger PL, Kazmierczak P, Cyran CC, Ricke J, Stief CG, Bartenstein P, Ruebenthaler J, Fabritius MP, Geyer T. Grawe F, et al. Among authors: bartenstein p. Eur Radiol. 2024 Feb;34(2):1157-1166. doi: 10.1007/s00330-023-10083-7. Epub 2023 Aug 25. Eur Radiol. 2024. PMID: 37624414 Free PMC article.
720 results